智通财经APP获悉，瑞穗分析师Graig Suvannavejh发表研报，将Neumora Therapeutics(NMRA.US)目标价从4美元上调至5美元，并维持“跑赢大盘”评级。
此次评级调整源于Neumora在7月9日宣布启动NMRA-861的一期临床试验。这项单次递增剂量/多次递增剂量(SAD/MAD)研究将在病情稳定的精神分裂症成年患者中展开。NMRA-861是一种高效、选择性正向变构调节剂(PAM)，该公司正开发其用于治疗精神分裂症及其他神经精神类疾病。
瑞穗预测，该药物有望于2034年在美国上市，经风险调整前测算，NMRA-861在2037年的销售额或将达到12亿美元。分析师认为，在当前股价水平下，该股具有较佳的风险收益比，这支撑了对Neumora Therapeutics的乐观预期。
作为一家处于临床阶段的生物技术企业，Neumora致力于通过整合神经科学与数据科学，为脑部疾病提供精准医疗解决方案。公司专注于针对中枢神经系统疾病相关治疗靶点开发创新药物。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.